These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10814979)

  • 1. A latent class mixed model for analysing biomarker trajectories with irregularly scheduled observations.
    Lin H; McCulloch CE; Turnbull BW; Slate EH; Clark LC
    Stat Med; 2000 May; 19(10):1303-18. PubMed ID: 10814979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovering subpopulation structure with latent class mixed models.
    McCulloch CE; Lin H; Slate EH; Turnbull BW
    Stat Med; 2002 Feb; 21(3):417-29. PubMed ID: 11813228
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of treatment efficacy using a Bayesian mixture piecewise linear model of longitudinal biomarkers.
    Zhao L; Feng D; Neelon B; Buyse M
    Stat Med; 2015 May; 34(10):1733-46. PubMed ID: 25630845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of an outcome using trajectories estimated from a linear mixed model.
    Maruyama N; Takahashi F; Takeuchi M
    J Biopharm Stat; 2009 Sep; 19(5):779-90. PubMed ID: 20183443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a mixture model allowing for smoothing functions of longitudinal trajectories.
    Ding M; Chavarro JE; Fitzmaurice GM
    Stat Methods Med Res; 2021 Feb; 30(2):549-562. PubMed ID: 33106119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parametric latent class joint model for a longitudinal biomarker and recurrent events.
    Han J; Slate EH; Peña EA
    Stat Med; 2007 Dec; 26(29):5285-302. PubMed ID: 17542002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Finite mixture modeling with mixture outcomes using the EM algorithm.
    Muthén B; Shedden K
    Biometrics; 1999 Jun; 55(2):463-9. PubMed ID: 11318201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian nonparametric latent class model for longitudinal data.
    Koo W; Kim H
    Stat Methods Med Res; 2020 Nov; 29(11):3381-3395. PubMed ID: 32536251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Joint latent class models for longitudinal and time-to-event data: a review.
    Proust-Lima C; Séne M; Taylor JM; Jacqmin-Gadda H
    Stat Methods Med Res; 2014 Feb; 23(1):74-90. PubMed ID: 22517270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regularized Latent Class Model for Joint Analysis of High-Dimensional Longitudinal Biomarkers and a Time-to-Event Outcome.
    Sun J; Herazo-Maya JD; Molyneaux PL; Maher TM; Kaminski N; Zhao H
    Biometrics; 2019 Mar; 75(1):69-77. PubMed ID: 30178494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes.
    Pauler DK; Finkelstein DM
    Stat Med; 2002 Dec; 21(24):3897-911. PubMed ID: 12483774
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint partially linear model for longitudinal data with informative drop-outs.
    Kim S; Zeng D; Taylor JM
    Biometrics; 2017 Mar; 73(1):72-82. PubMed ID: 27479944
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mixed-effects regression models for studying the natural history of prostate disease.
    Pearson JD; Morrell CH; Landis PK; Carter HB; Brant LJ
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):587-601. PubMed ID: 7517570
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Joint analysis of left-censored longitudinal biomarker and binary outcome via latent class modeling.
    Li M; Kong L
    Stat Med; 2018 Jun; 37(13):2162-2173. PubMed ID: 29611202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statistical models for longitudinal biomarkers of disease onset.
    Slate EH; Turnbull BW
    Stat Med; 2000 Feb; 19(4):617-37. PubMed ID: 10694740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial prostate specific antigen, free-to-total prostate specific antigen ratio and complexed prostate specific antigen for the diagnosis of prostate cancer.
    Ellis WJ; Etzioni R; Vessella RL; Hu C; Goodman GE
    J Urol; 2001 Jul; 166(1):93-8; discussion 98-9. PubMed ID: 11435831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining longitudinal studies of PSA.
    Inoue LY; Etzioni R; Slate EH; Morrell C; Penson DF
    Biostatistics; 2004 Jul; 5(3):483-500. PubMed ID: 15208207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Latent Class Approach to Modeling Trajectories of Health Care Cost in Pediatric Cystic Fibrosis.
    Levy JF; Rosenberg MA
    Med Decis Making; 2019 Jul; 39(5):593-604. PubMed ID: 31409187
    [No Abstract]   [Full Text] [Related]  

  • 19. Examining trajectories of anxiety in men with prostate cancer faced with complex treatment decisions.
    Costa DSJ; Sundaresan P; Ager B; Turner S; Butow P
    Support Care Cancer; 2019 Feb; 27(2):567-571. PubMed ID: 30014194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AR(1) latent class models for longitudinal count data.
    Henderson NC; Rathouz PJ
    Stat Med; 2018 Dec; 37(29):4441-4456. PubMed ID: 30132947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.